Sionna Therapeutics, Inc.'s Lock-Up Period Will Expire on August 6th (NASDAQ:SION)

Key Points

• The **lock-up period** for Sionna Therapeutics, Inc. will expire on **August 6th**, allowing major shareholders and insiders to sell their shares.
• Sionna Therapeutics has been downgraded from a "hold" to a "**sell**" rating by Wall Street Zen as of May 22nd.
• Shares opened at **$18.33** with a one-year price range of **$7.26 to $25.19**, and the company reported a quarterly loss of **($0.62)** EPS, missing estimates by **($0.17)**.

Sionna Therapeutics' (NASDAQ:SION - Get Free Report) lock-up period will expire on Wednesday, August 6th. Sionna Therapeutics had issued 10,588,233 shares in its public offering on February 7th. The total size of the offering was $190,588,194 based on an initial share price of $18.00. After the end of the company's lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Analyst Ratings Changes

Separately, Wall Street Zen downgraded Sionna Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd.

Sionna Therapeutics Stock Up 1.0%

Shares of NASDAQ:SION traded up $0.16 during trading on Friday, reaching $16.92. 118,284 shares of the company's stock traded hands, compared to its average volume of 134,392. Sionna Therapeutics has a fifty-two week low of $7.26 and a fifty-two week high of $25.19. The stock has a 50-day simple moving average of $17.14.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.17).

Insiders Place Their Bets

In other Sionna Therapeutics news, major shareholder Tpg Gp A, Llc bought 60,000 shares of the firm's stock in a transaction on Friday, June 27th. The shares were acquired at an average cost of $15.84 per share, with a total value of $950,400.00. Following the purchase, the insider directly owned 6,744,962 shares of the company's stock, valued at $106,840,198.08. This trade represents a 0.90% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 3.90% of the stock is owned by company insiders.

Institutional Trading of Sionna Therapeutics

Several institutional investors have recently made changes to their positions in the company. RA Capital Management L.P. purchased a new stake in shares of Sionna Therapeutics during the 1st quarter valued at approximately $109,258,000. TPG GP A LLC acquired a new position in shares of Sionna Therapeutics in the first quarter worth $69,925,000. Atlas Venture Life Science Advisors LLC acquired a new position in shares of Sionna Therapeutics in the first quarter worth $38,639,000. Aberdeen Group plc lifted its position in shares of Sionna Therapeutics by 27.4% during the 2nd quarter. Aberdeen Group plc now owns 950,547 shares of the company's stock worth $16,492,000 after purchasing an additional 204,583 shares during the last quarter. Finally, Jennison Associates LLC purchased a new stake in shares of Sionna Therapeutics during the 1st quarter worth $8,995,000.

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.